Association of CHRNA5-A3-B4 SNP rs2036527 with smoking cessation therapy response in African-American smokers

Clinical Pharmacology and Therapeutics

Volumn 96, Issue 2, 2014, Pages 256-265

  Zhu, A Z X ^a   Zhou, Q ^a   Cox, L S ^b   David, S P ^c,d   Ahluwalia, J S ^e   Benowitz, N L ^f,g   Tyndale, R F ^a,h  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d SRI INTERNATIONAL   (United States)

^e UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^f SAN FRANCISCO GENERAL HOSPITAL   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; NICOTINE GUM; PLACEBO;

AFRICAN AMERICAN; ALLELE; ARTICLE; CHRNA5 GENE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; GENE; GENETIC ASSOCIATION; HUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SMOKING; SMOKING CESSATION; TOBACCO CONSUMPTION; TOBACCO DEPENDENCE; TREATMENT RESPONSE;

AFRICAN AMERICANS; BUPRENORPHINE; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GENETIC ASSOCIATION STUDIES; HUMANS; MALE; NERVE TISSUE PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, NICOTINIC; SMOKING; SMOKING CESSATION; TOBACCO USE CESSATION PRODUCTS; TREATMENT OUTCOME;

EID: 84904855644     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2014.88     Document Type: Article

References (35)

1. Benowitz, N.L. Nicotine addiction. N. Engl. J. Med. 362, 2295-2303 (2010
2. Xian, H. et al. The heritability of failed smoking cessation and nicotine withdrawal in twins who smoked and attempted to quit. Nicotine Tob. Res. 5, 245-254 (2003 (Pubitemid 36547008)
3. Gold, A.B., Wileyto, E.P., Lori, A., Conti, D., Cubells, J.F. & Lerman, C. Pharmacogenetic association of the galanin receptor (GALR1) SNP rs2717162 with smoking cessation. Neuropsychopharmacology 37, 1683-1688 (2012
4. Hutchison, K.E. et al. CHRNA4 and tobacco dependence: From gene regulation to treatment outcome. Arch. Gen. Psychiatry 64, 1078-1086 (2007 (Pubitemid 47360853)
5. Lerman, C. et al. Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: Results of two randomized clinical trials. Neuropsychopharmacology 31, 231-242 (2006 (Pubitemid 43250960)
6. Ahluwalia, J.S. et al. The effects of nicotine gum and counseling among African American light smokers: A 2 x 2 factorial design. Addiction 101, 883-891 (2006 (Pubitemid 43727522)
7. Munafò, M.R. et al.; EPIC Study Group. Association between genetic variants on chromosome 15q25 locus and objective measures of tobacco exposure. J. Natl. Cancer Inst. 104, 740-748 (2012
8. Amos, C.I. et al. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat. Genet. 40, 616-622 (2008 (Pubitemid 351601203)
9. Thorgeirsson, T.E. et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 452, 638-642 (2008 (Pubitemid 351483366)
10. Thorgeirsson, T.E. et al.; ENGAGE Consortium Sequence variants at CHRNB3-CHRNA6 and CYP2A6 affect smoking behavior. Nat. Genet. 42, 448-453 (2010
11. Chen, L.S. et al. Smoking and genetic risk variation across populations of European, Asian, and African American ancestry-A meta-Analysis of chromosome 15q25. Genet. Epidemiol. 36, 340-351 (2012
12. Zhu, A.Z., Renner, C.C., Hatsukami, D.K., Benowitz, N.L. & Tyndale, R.F. CHRNA5-A3-B4 genetic variants alter nicotine intake and interact with tobacco use to influence body weight in Alaska Native tobacco users. Addiction 108, 1818-1828 (2013
13. Wassenaar, C.A., Dong, Q., Wei, Q., Amos, C.I., Spitz, M.R. & Tyndale, R.F. Relationship between CYP2A6 and CHRNA5-CHRNA3-CHRNB4 variation and smoking behaviors and lung cancer risk. J. Natl. Cancer Inst. 103, 1342-1346 (2011
14. Freathy, R.M. et al. A common genetic variant in the 15q24 nicotinic acetylcholine receptor gene cluster (CHRNA5-CHRNA3-CHRNB4) is associated with a reduced ability of women to quit smoking in pregnancy. Hum. Mol. Genet. 18, 2922-2927 (2009
15. Munafò, M.R., Johnstone, E.C., Walther, D., Uhl, G.R., Murphy, M.F. & Aveyard, P. CHRNA3 rs1051730 genotype and short-Term smoking cessation. Nicotine Tob. Res. 13, 982-988 (2011
16. Sarginson, J.E. et al. Markers in the 15q24 nicotinic receptor subunit gene cluster (CHRNA5-A3-B4) predict severity of nicotine addiction and response to smoking cessation therapy. Am. J. Med. Genet. B Neuropsychiatr. Genet. 156B, 275-284 (2011
17. Chen, L.S. et al. Interplay of genetic risk factors (CHRNA5-CHRNA3- CHRNB4) and cessation treatments in smoking cessation success. Am. J. Psychiatry 169, 735-742 (2012
18. King, D.P. et al. Smoking cessation pharmacogenetics: Analysis of varenicline and bupropion in placebo-controlled clinical trials. Neuropsychopharmacology 37, 641-650 (2012
19. Saccone, N.L. et al. Multiple independent loci at chromosome 15q25.1 affect smoking quantity: A meta-Analysis and comparison with lung cancer and COPD. PLoS Genet. 6, e1001053 (2010
20. Bergen, A.W. et al. Nicotinic acetylcholine receptor variation and response to smoking cessation therapies. Pharmacogenet. Genomics 23, 94-103 (2013
21. David, S.P. et al. Genome-wide meta-Analyses of smoking behaviors in African Americans. Transl. Psychiatry 2, e119 (2012
22. Li, M.D., Xu, Q., Lou, X.Y., Payne, T.J., Niu, T. & Ma, J.Z. Association and interaction analysis of variants in CHRNA5/CHRNA3/CHRNB4 gene cluster with nicotine dependence in African and European Americans. Am. J. Med. Genet. B Neuropsychiatr. Genet. 153B, 745-756 (2010
23. Amos, C.I. et al. Nicotinic acetylcholine receptor region on chromosome 15q25 and lung cancer risk among African Americans: A case-control study. J. Natl. Cancer Inst. 102, 1199-1205 (2010
24. Cox, L.S. et al. Bupropion for smoking cessation in African American light smokers: A randomized controlled trial. J. Natl. Cancer Inst. 104, 290-298 (2012
25. Liu, J.Z. et al.; Wellcome Trust Case Control Consortium Meta-Analysis and imputation refines the association of 15q25 with smoking quantity. Nat. Genet. 42, 436-440 (2010
26. Benowitz, N.L., Dains, K.M., Dempsey, D., Wilson, M. & Jacob, P. Racial differences in the relationship between number of cigarettes smoked and nicotine and carcinogen exposure. Nicotine Tob. Res. 13, 772-783 (2011
27. Fowler, C.D., Lu, Q., Johnson, P.M., Marks, M.J. & Kenny, P.J. Habenular a5 nicotinic receptor subunit signalling controls nicotine intake. Nature 471, 597-601 (2011
28. Berrettini, W.H. & Doyle, G.A. The CHRNA5-A3-B4 gene cluster in nicotine addiction. Mol. Psychiatry 17, 856-866 (2012
29. Slemmer, J.E., Martin, B.R. & Damaj, M.I. Bupropion is a nicotinic antagonist. J. Pharmacol. Exp. Ther. 295, 321-327 (2000
30. Zhu, A.Z. et al. CYP2B6 and bupropion's smoking-cessation pharmacology: The role of hydroxybupropion. Clin. Pharmacol. Ther. 92, 771-777 (2012
31. Ho, M.K. et al. Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers. Clin. Pharmacol. Ther. 85, 635-643 (2009
32. Haiman, C.A. et al. Ethnic and racial differences in the smoking-related risk of lung cancer. N. Engl. J. Med. 354, 333-342 (2006 (Pubitemid 43145058)
33. Zhu, A.Z. et al. Alaska Native smokers and smokeless tobacco users with slower CYP2A6 activity have lower tobacco consumption, lower tobaccospecific nitrosamine exposure and lower tobacco-specific nitrosamine bioactivation. Carcinogenesis 34, 93-101 (2013
34. Benowitz, N.L., Jacob, P. 3rd, Fong, I. & Gupta, S. Nicotine metabolic profile in man: Comparison of cigarette smoking and transdermal nicotine. J. Pharmacol. Exp. Ther. 268, 296-303 (1994 (Pubitemid 24039102)
35. Benowitz, N.L., Dains, K.M., Dempsey, D., Havel, C., Wilson, M. & Jacob, P. 3rd. Urine menthol as a biomarker of mentholated cigarette smoking. Cancer Epidemiol. Biomarkers Prev. 19, 3013-3019 (2010.